David C. Hastings - 14 Feb 2025 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Role
Chief Financial Officer
Signature
/s/ David C. Hastings
Issuer symbol
ABUS
Transactions as of
14 Feb 2025
Transactions value $
$0
Form type
4
Date filed
19 Feb 2025, 18:25
Previous filing
05 Feb 2025
Next filing
30 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABUS Common Shares Award $0 +90.1K +56.41% $0.00 250K 14 Feb 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABUS Stock Option (Right to Buy) Award $0 +366K $0.00 366K 14 Feb 2025 Common Shares 366K $3.29 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.
F2 Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
F3 This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.